Skip to main content
    PeptideAuthority
    Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
    Share:X PostLinkedIn
    Neuropeptides•Updated 2026-02-01•5 min read

    What Is Vasopressin? Benefits, Research & Safety

    A hormone essential for water balance and blood pressure regulation, also involved in social behavior and stress responses.

    Share:X PostLinkedIn
    Also known as:
    Antidiuretic Hormone
    ADH
    Arginine Vasopressin
    AVP
    AStrong human evidenceUK: Prescription-only (UK POM)WADA: Prohibited in sport

    UK summary: Endogenous hormone. Synthetic analogues (vasopressin itself for vasopressor / GI bleeding use; desmopressin for diabetes insipidus and nocturnal enuresis) are UK prescription-only medicines. Prohibited under WADA S5 (diuretics / masking agents).

    Quick Facts

    Category
    Neuropeptides
    Half-Life
    10-20 minutes in plasma (vasopressin); longer for desmopressin
    UK Status
    Vasopressin and desmopressin licensed for various indications including diabetes insipidus, nocturnal enuresis, and haemostasis.
    EU Status
    Approved for similar indications across member states.

    Overview

    Vasopressin, also known as antidiuretic hormone (ADH) or arginine vasopressin (AVP), is a nine-amino acid peptide hormone produced in the hypothalamus and released from the posterior pituitary. It is structurally very similar to oxytocin, differing by only two amino acids. Vasopressin plays critical roles in maintaining body water balance and blood pressure. Its primary physiological function is promoting water reabsorption in the kidneys, thereby concentrating urine and preventing dehydration. It also causes vasoconstriction, which can increase blood pressure. Beyond these classical endocrine roles, vasopressin acts as a neurotransmitter in the brain, where it influences social behaviour, aggression, pair bonding (particularly in males), stress responses, and memory. The interplay between vasopressin and oxytocin in regulating social behaviour is an active area of research. Synthetic vasopressin analogues have important medical applications. Desmopressin (DDAVP) is used to treat diabetes insipidus, bedwetting, and von Willebrand disease. Vasopressin itself is used in critical care for vasodilatory shock and cardiac arrest. Research continues into vasopressin's roles in psychiatric conditions, autism, and social behaviour, though therapeutic applications beyond established uses remain investigational.
    Evidence standards summary

    Vasopressin — evidence and risk at a glance

    Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.

    01Evidence snapshot

    AStrong human evidenceOverall grade against our evidence grading methodology.

    Endogenous hormone. Synthetic analogues (vasopressin itself for vasopressor / GI bleeding use; desmopressin for diabetes insipidus and nocturnal enuresis) are UK prescription-only medicines. Prohibited under WADA S5 (diuretics / masking agents).

    02Human evidence grade

    AStrong human evidenceStrength of evidence from published human trials.

    03Preclinical evidence grade

    AStrong human evidenceAnimal-model and in-vitro evidence quality.

    04Regulatory status

    • UK: Vasopressin and desmopressin licensed for various indications including diabetes insipidus, nocturnal enuresis, and haemostasis.
    • EU: Approved for similar indications across member states.
    • Notes: Vasopressin and analogues have well-established approved uses. Desmopressin is widely available. Use for behavioural modification or social enhancement is not approved and remains investigational.

    05Approved medical uses

    • Diabetes insipidus (desmopressin — MHRA-licensed POM).
    • Nocturnal enuresis (desmopressin — licensed POM).
    • Vasopressor support in shock (vasopressin IV — hospital use).

    06Unapproved / promotional claims

    • 'Memory peptide' supplements.
    • Social-cognition enhancer for healthy adults.

    07Common internet claims

    • Nasal-vasopressin marketed by biohacker forums as a memory-enhancing nootropic.

    08Claim vs evidence

    ClaimEvidenceHuman evidence?Regulatory concernSafer wording
    “Vasopressin supplements improve memory or focus”ENoHighNative vasopressin is degraded orally; nasal vasopressin is a UK POM and not appropriate for self-administration.

    09Safety uncertainty score

    Moderate

    Safety profile partly characterised; some signals from observational or preclinical data.

    10Known adverse signals

    • Hyponatraemia risk (especially with fluid intake combined with desmopressin).
    • Cardiovascular effects (BP, vasoconstriction).
    • Contraindications include cardiovascular disease, hyponatraemia, SIADH.

    11Drug-interaction uncertainty

    Moderate

    Some interaction data published; check with a prescriber for your specific medicines.

    12Anti-doping status

    WADA: Prohibited in sportWADA strict-liability framing applies.

    13UK legal position

    UK: Prescription-only (UK POM)

    Vasopressin and desmopressin licensed for various indications including diabetes insipidus, nocturnal enuresis, and haemostasis.

    14EU legal position

    Approved for similar indications across member states.

    15What this page cannot tell you

    • Whether a grey-market nasal-vasopressin product contains the labelled compound at the labelled concentration.
    • Whether off-label cognitive-enhancement use is safe long-term.

    16Last reviewed

    Last reviewed:

    Next review due:

    Spotted an error or something out of date? Send a correction.

    17Citation quality score

    AStrong human evidenceQuality of the sources we cite, graded against the evidence grading methodology.

    18Research gaps

    • Cognitive-enhancement RCTs in healthy adults are limited; replication poor.

    19Safer alternatives / established care pathways

    • GP review for any genuine memory or focus concern.
    • Adult ADHD assessment if attention is the issue.

    Related Safety Centre page → Prescription-only medicines

    20Doctor discussion prompts

    Questions to ask a qualified clinician

    These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

    • Is vasopressin (or desmopressin) appropriate for my situation?

    Discovery & History

    Vasopressin was discovered in the early 20th century alongside oxytocin. Researchers studying pituitary extracts noticed effects on blood pressure (pressor effects) and water retention (antidiuretic effects). Oliver and Schäfer first demonstrated pressor effects of pituitary extracts in 1895. Further work by various researchers characterised the antidiuretic properties, leading to the name "antidiuretic hormone." Vincent du Vigneaud, who had determined oxytocin's structure, also elucidated vasopressin's structure and synthesised it. The structural similarity to oxytocin (differing in only two amino acids) was noted, though the hormones have distinct biological roles. Clinical use of vasopressin and its analogues developed over the 20th century. Desmopressin (DDAVP), a synthetic analogue with enhanced antidiuretic activity and reduced pressor effects, became a key treatment for diabetes insipidus. Research into vasopressin's behavioural effects accelerated following studies in prairie voles by Tom Insel and Larry Young, which demonstrated that vasopressin receptor distribution predicted male bonding behaviour. This sparked interest in human social behaviour applications. Current research explores the vasopressin system in autism, anxiety, and aggression, though translating animal findings to human therapeutics remains challenging.

    Mechanism of Action

    Vasopressin acts through three main receptor subtypes with distinct tissue distributions and functions: **V1a Receptors (V1aR)** The predominant receptor type in peripheral vessels and brain: - Blood vessels: Vasoconstriction, increasing blood pressure - Liver: Glycogenolysis - Brain: Social behaviour, aggression, pair bonding, anxiety - Platelets: Aggregation **V2 Receptors (V2R)** Found primarily in the kidney: - Collecting duct: Insertion of aquaporin-2 water channels - Results in water reabsorption and concentrated urine - Primary mechanism for antidiuretic effect - Also affects von Willebrand factor and Factor VIII release **V1b Receptors (V1bR, also called V3)** Present in pituitary and brain: - Pituitary: Modulates ACTH release (stress response) - Brain: Involved in stress responses and emotional regulation **Neurotransmitter Effects** In the brain, vasopressin: - Modulates activity in social brain regions - Interacts with oxytocin systems - Affects memory consolidation in hippocampus - Influences aggressive and territorial behaviour

    Researched Benefits

    Based on preclinical and clinical research findings:

    • 1
      Effective treatment for central diabetes insipidus (as desmopressin)
    • 2
      Management of nocturnal enuresis/bedwetting (desmopressin)
    • 3
      Treatment of von Willebrand disease (desmopressin)
    • 4
      Vasopressor support in septic shock
    • 5
      Cardiac arrest protocols
    • 6
      Research into social behaviour modulation
    • 7
      Potential applications in psychiatric conditions (investigational)

    Claim vs Evidence

    How popular claims about Vasopressin stack up against the current research, graded using our public evidence grading methodology.

    ClaimEvidenceHuman evidence?Regulatory concernSafer wording
    “Vasopressin supplements improve memory or focus”ENoHighNative vasopressin is degraded orally; nasal vasopressin is a UK POM and not appropriate for self-administration.

    Theoretical Dosing & Protocols

    ⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
    Theoretical DosageVaries greatly by indication and analogue used
    FrequencyIndication-dependent; from once daily to continuous infusion
    DurationChronic for diabetes insipidus; acute for critical care
    NotesVasopressin and its analogues (especially desmopressin) have established medical uses. Use must be under medical supervision with appropriate monitoring. Water intake restriction may be necessary to prevent water intoxication.

    Administration Routes

    Routes studied in research settings (educational only):

    • Intravenous (critical care, severe diabetes insipidus)
    • Subcutaneous (some protocols)
    • Intranasal (desmopressin for diabetes insipidus, bedwetting)
    • Oral (desmopressin tablets available)
    Half-LifeStability
    10-20 minutes in plasma (vasopressin); longer for desmopressinInjectable solutions per manufacturer specifications; desmopressin formulations have defined stability

    Safety Profile & Known Risks

    Commonly Reported Side Effects

    • Water retention
    • Headache
    • Nausea
    • Abdominal cramps
    • Nasal congestion (intranasal route)
    • Hypertension (vasopressin)

    Rare Risks & Concerns

    • Water intoxication and hyponatraemia (serious)
    • Seizures from hyponatraemia
    • Cardiac ischaemia (vasoconstriction)
    • Allergic reactions

    Contraindications

    • Conditions with fluid/electrolyte imbalances
    • Coronary artery disease (relative)
    • Hyponatraemia
    • Polydipsia or inappropriate thirst mechanisms

    UK & EU Regulatory Context

    🇬🇧 United Kingdom

    Vasopressin and desmopressin licensed for various indications including diabetes insipidus, nocturnal enuresis, and haemostasis.

    🇪🇺 European Union

    Approved for similar indications across member states.

    Vasopressin and analogues have well-established approved uses. Desmopressin is widely available. Use for behavioural modification or social enhancement is not approved and remains investigational.

    Clinical Studies Summary

    DDAVP response and its determinants in bleeding disorders: a systematic review and meta-analysis.

    The remaining authors declare no competing financial interests. A complete list of the members of the SYMPHONY consortium appears in “Appendix.

    Blood. 2025View on PubMed

    Central diabetes insipidus (vasopressin deficiency) after surgery for pituitary tumours: a systematic review and meta-analysis.

    Following TSS, a small proportion of patients with pituitary adenoma have permanent AVP-D (2%), but prevalence reaches 30% in ones with craniopharyngioma and 14% in those with RCC. Diagnostic criteria for post-operative AVP-D remain variable affecting reported rates of this condition.

    Eur J Endocrinol. 2024View on PubMed

    Non-adrenergic vasopressors for vasodilatory shock or perioperative vasoplegia: a meta-analysis of randomized controlled trials.

    Administration of non-adrenergic vasopressors was significantly associated with reduced mortality in patients with septic shock. However, no single agent achieved statistical significance in separate analyses.

    Crit Care. 2024View on PubMed

    Effect of vasopressin injection technique on ovarian reserve during laparoscopic cystectomy of ovarian endometriomas: a systematic review and meta-analysis of randomized controlled trials.

    Vasopressin injection during laparoscopic cystectomy of ovarian endometriomas is effective in reducing blood loss amount and frequency of coagulation, as well as protecting the ovarian reserve. More trials are encouraged to confirm our findings.

    Minerva Obstet Gynecol. 2024View on PubMed

    THE EFFICACY AND SAFETY OF VASOPRESSORS FOR SEPTIC SHOCK PATIENTS: A SYSTEMIC REVIEW AND NETWORK META-ANALYSIS.

    The results of this network meta-analysis suggest that norepinephrine plus dobutamine is associated with a lower risk of 28-day mortality in septic shock patients than other vasoactive medications, and the use of dopamine is associated with a higher risk of 28-day mortality due to septic shock than norepinephrine, terlipressin, and vasopressin.

    Shock. 2023View on PubMed

    Therapeutic effects of vasopressin on cardiac arrest: a systematic review and meta-analysis.

    Our study failed to demonstrate increased benefit from vasopressin with or without epinephrine compared with the standard of care. However, vasopressin as a part of VSE is associated with the improvement of ROSC in patients with IHCA, and the benefit on mid-term survival or mid-term good neurological outcome is uncertain.

    BMJ Open. 2023View on PubMed

    Registered Trials & Regulatory Status

    Registered trials
    47
    Currently recruiting
    8
    Furthest phase
    Phase 4
    Approved product
    Yes
    VASOPRESSIN, Vasopressin

    17 of 23 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.

    Systematic Adjunction of Vasopressine in Septic Shock

    PHASE3

    Status: Not Yet Recruiting · 120 participants · Assistance Publique Hopitaux De Marseille

    Conditions: Septic Shock

    No results postedNCT07052084

    Intracervical Vasopressin

    PHASE4

    Status: Recruiting · 50 participants · Prisma Health-Upstate

    Conditions: Retained Products of Conception

    No results postedNCT07102615

    Vasopressin Hemodynamic Response as a Septic Shock Subphenotype Indicator

    N/A

    Status: Terminated · 2 participants · The Cleveland Clinic

    Conditions: Shock, Septic

    No results postedNCT06426407

    Effects of Intranasal Oxytocin on Sexual Well-Being in Patients With Arginine Vasopressin Deficiency and Healthy Controls

    PHASE2

    Status: Recruiting · 42 participants · University Hospital, Basel, Switzerland

    Conditions: Arginine Vasopressin Deficiency, Central Diabetes Insipidus, Oxytocin Deficiency

    No results postedNCT06808516

    Vasopressin in the Elderly: Physiological Changes in Neuroendocrine Function and Urinary Secretion in Healthy Aging

    NA

    Status: Completed · 32 participants · University Hospital, Basel, Switzerland

    Conditions: Healthy Ageing

    No results postedNCT06930300

    Low-dose Arginine-vasopressin Supplementation on Post-transplant Acute Kidney Injury After Liver Transplantation (AVENIR Trial)

    PHASE3

    Status: Recruiting · 304 participants · Assistance Publique - Hôpitaux de Paris

    Conditions: Acute Kidney Injury Post Liver Transplantation

    No results postedNCT06344442

    Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis

    PHASE3

    Status: Recruiting · 2,800 participants · Hospital do Coracao

    Conditions: Septic Shock

    No results postedNCT06464510

    Norepinephrine Equivalent Dose of Vasopressin, Phenylephrine and Epinephrine in Septic Shock

    N/A

    Status: Recruiting · 100 participants · Sanjay Gandhi Postgraduate Institute of Medical Sciences

    Conditions: Septic Shock

    No results postedNCT06499467

    Registry of Patients in Shock Treated With Vasopressin

    N/A

    Status: Unknown · 500 participants · Hospital Universitario 12 de Octubre

    Conditions: Vasopressin Causing Adverse Effects in Therapeutic Use, Shock, Vasopressor Adverse Reaction

    No results postedNCT06422975

    Dexmedetomidine and Vasopressin in Septic Shock

    PHASE2

    Status: Unknown · 260 participants · Mansoura University

    Conditions: Sepsis, Septic Shock

    No results postedNCT06302998

    Vasopressin Versus Tranexamic Acid for Control of Blood Loss Related to Abdominal Hysterectomy

    PHASE4

    Status: Unknown · 387 participants · Al-Azhar University

    Conditions: Uterine Surgery

    No results postedNCT06290596

    Vasopressin vs. Uterine Artery Clamping for Laparoscopic Cesarean Scar Niche Repair

    PHASE2

    Status: Completed · 30 participants · Zagazig University

    Conditions: Cesarean Section Complications

    No results postedNCT07446933

    Adverse event reports (FDA FAERS)

    • drug ineffective1,322
    • hypotension546
    • off label use529
    • cardiogenic shock408
    • sepsis407
    • multiple organ dysfunction syndrome389
    • condition aggravated374
    • toxicity to various agents330
    • acute kidney injury327
    • stress312

    FDA FAERS spontaneous reports. A report is not proof the substance caused the event, and an absence of reports is not evidence of safety.

    Source: ClinicalTrials.gov and openFDA. Updated automatically.

    Looking for Vasopressin?

    Source research-grade Vasopressin from a trusted UK supplier — third-party tested with certificate of analysis.

    View at Supplier

    Frequently Asked Questions

    Questions to ask a qualified clinician about Vasopressin

    These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

    • Is vasopressin (or desmopressin) appropriate for my situation?

    UK regulatory & safety context

    Prescription-only medicines

    Safety Centre guide

    Related Peptides

    Oxytocin

    A natural hormone and neurotransmitter involved in social bonding, childbirth, lactation, and emotional regulation with therapeutic applications.

    Learn more

    ACTH

    A pituitary hormone that stimulates cortisol production, used diagnostically and therapeutically for various conditions including infantile spasms.

    Learn more

    VIP

    A neuropeptide with vasodilatory, anti-inflammatory, and immunomodulatory properties, researched for various therapeutic applications.

    Learn more

    Explore More Peptides

    Browse our comprehensive database of research-backed peptide profiles.